Podcast Alert: ''Treating inoperable heart disease via TMR (Transmyocardial Revascularization) and autologous stem cells''

Share Article

Ronald Trahan Associates ("RTA") Inc. announced today the availability of a podcast at entitled, "Treating inoperable heart disease via TMR (Transmyocardial Revascularization) and autologous stem cells".

    'TMR' is a surgical procedure used to treat inoperable heart disease in people with persistent angina who cannot be relieved by any other method, including angioplasty, stenting, or coronary artery bypass graft (CABG) surgery. In this episode, Keith Allen, MD, of Mid America Heart Institute at St. Luke's Hospital in Kansas City, Missouri, discusses how a new treatment option--TMR combined with autologous stem cell therapy--may enhance angiogenesis in this difficult-to-treat patient population who have diffuse coronary artery disease and either have no conventional revascularization options or who, more commonly, would be incompletely revascularized by CABG alone.

Until recently, it has been difficult to process and concentrate a clinically significantly dose of adult stem cells from a patient's own bone marrow at the point-of-care. Now, technology from Harvest Technologies ( is the world's first technique that produces clinically significant amounts of stem and precursor cells from a small aspirate of autologous bone marrow in just 15 minutes. Injected autologous adult stem cell concentrates from bone marrow have been used successfully by Dr. Allen in combination with TMR to treat inoperable heart disease in a 74-year-old female patient, which is discussed in the podcast. Dr. Allen performed the procedure featured in the podcast in Egypt.

Availability of this podcast begins today. To listen to this podcast, go to and click-on "Podcasts." After listening, podcatchers are invited to post their comments about this podcast at:

Since 1992, Ronald Trahan Associates ("RTA") Inc. has been providing public relations and investor relations counsel and services to big and small companies, both public and private, in the Life Sciences industry.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ron Trahan
Visit website